Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: J Psychosom Res. 2019 Jan 7;118:18–26. doi: 10.1016/j.jpsychores.2019.01.002

Table 2.

Symptoms of Anxiety and Depression and Use of Anxiolytic-Hypnotics and Antidepressants by GOLD ABCD Groups (n=5331)

Exacerbation History GOLD ABCD Groups
≥2
or
≥1
Leading to
Hospital
Admission		 C
(n=1007)
Anxiety Symptoms: 24.6%
Depressive Symptoms: 14.1%
Anxiolytic-Hypnotics: 8.8%
Antidepressants: 15.3%
Unmedicated Symptoms: 19.9%		 D
(n=905)
Anxiety Symptoms: 26.6%
Depressive Symptoms: 19.7%
Anxiolytic-Hypnotics: 12.4%
Antidepressants: 20.0%
Unmedicated Symptoms: 23.0%
0 or 1
Not Leading to
Hospital
Admission		 A
(n=2180)
Anxiety Symptoms 9:2%
Depressive Symptoms: 3.8%
Anxiolytic-Hypnotics: 6.0%
Antidepressants: 14.3%
Unmedicated Symptoms: 7.5%		 B
(n=1239)
Anxiety Symptoms 29.2%
Depressive Symptoms: 23.6%
Anxiolytic-Hypnotics: 9.3%
Antidepressants: 17.2%
Unmedicated Symptoms: 25.0%
mMRC 0–1
or
CAT<10		 mMRC ≥2
or
CAT ≥10
Symptoms

Abbreviations: mMRC = modified Medical Research Council Dyspnea scale; CAT = COPD Assessment Test